<SEC-DOCUMENT>0001144204-17-009707.txt : 20170217
<SEC-HEADER>0001144204-17-009707.hdr.sgml : 20170217
<ACCEPTANCE-DATETIME>20170217080020
ACCESSION NUMBER:		0001144204-17-009707
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170217
FILED AS OF DATE:		20170217
DATE AS OF CHANGE:		20170217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36000
		FILM NUMBER:		17619763

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		5 HACHAROSHET ST.
		CITY:			RAANANA
		STATE:			L3
		ZIP:			4365603
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v459923_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of February, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: <B>001-36000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>XTL Biopharmaceuticals Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>5 HaCharoshet St., Raanana,<BR>
4365603, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings">x</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. is hereby incorporated by reference into the registration statements on Form S-8 (File No. 333-148085,
File No. 333-148754 and File No. 333-154795) and Form F-3 (File No. 333-194338).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 17, 2017, XTL Biopharmaceuticals
Ltd. announced it has entered into definitive agreements with institutional investors for the sale of securities with gross proceeds
of $2,500,000. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exhibit Index</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 91%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated February 17, 2017</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>XTL BIOPHARMACEUTICALS LTD.&nbsp;</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: February 17, 2017 </FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Josh Levine</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh Levine</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v459923_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>XTL BIOPHARMACEUTICALS ANNOUNCES $2.5
MILLION REGISTERED DIRECT OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Raanana, Israel, February 17, 2017 &ndash;
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB)</B> (TASE:XTLB.TA) (&ldquo;XTL&rdquo; or the &ldquo;Company&rdquo;)<B>, </B>a clinical-stage
biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has entered into definitive agreements
with institutional investors to receive gross proceeds of $2.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the offering, the Company
will issue 1,000,000 registered American Depository Shares (ADSs) at a purchase price of $2.50 per ADS in a registered direct offering.
Additionally, for each ADS purchased by investors, the investors will receive an unregistered warrant to purchase one ADS. The
warrants have an exercise price of $4.10 per ADS, shall be exercisable six months following the issuance date and will expire five
and one-half years from the issuance date. The closing of the offering is expected to take place on or about February 23, 2017,
subject to the satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rodman &amp; Renshaw, a unit of H.C. Wainwright
&amp; Co., is acting as the exclusive placement agent in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ADSs described above (but not the warrants
or the ADSs underlying the warrants) are being offered pursuant to a shelf registration statement (File No. 333-194338) which became
effective on April 4, 2014. Such ADSs may be offered only by means of a prospectus, including a prospectus supplement, forming
a part of the effective registration statement. The warrants described above were offered in a private placement under Section
4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;), and Regulation D promulgated thereunder and, along with
the ADSs issuable upon their exercise, have not been registered under the Act, and may not be offered or sold in the United States
absent registration with the SEC or an applicable exemption from such registration requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute
an offer to sell or the solicitation of an offer to buy any of the securities described herein. There shall not be any offer, solicitation
of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be
unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The Company will file
a prospectus supplement with the SEC relating to such ADSs, and following such filing, copies of the prospectus supplement and
the accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov, or from
H.C. Wainwright &amp; Co. by e-mailing placements@hcwco.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>About XTL Biopharmaceuticals Ltd</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">XTL Biopharmaceuticals
Ltd. is a&nbsp;clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune
diseases. The Company&rsquo;s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of autoimmune diseases
including systemic lupus erythematosus (SLE) and Sj&ouml;gren&rsquo;s Syndrome (SS). The few treatments currently on the market
for these diseases are not effective enough for most patients and some have significant side effects. hCDR1 has robust clinical
data in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than&nbsp;40 peer
reviewed scientific journals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">XTL is&nbsp;traded
on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). XTL shares are included in the following
indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 25%; padding: 0; text-align: center">&nbsp;</TD><TD STYLE="width: 50%; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XTL Biopharmaceuticals Ltd.</FONT></TD><TD STYLE="width: 25%; padding: 0; text-align: center">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding: 0; text-align: center">&nbsp;</TD><TD STYLE="padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5 Hacharoshet Street, Raanana, 43656, Israel</FONT></TD><TD STYLE="padding: 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding: 0; text-align: center">&nbsp;</TD><TD STYLE="padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tel: +972 9 955 7080; email: <U>ir@xtlbio.com</U></FONT></TD><TD STYLE="padding: 0; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Forward-Looking Statements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain forward-looking
statements, about XTL&rsquo;s expectations, beliefs or intentions regarding, among other things, its product development efforts,
business, financial condition, results of operations, strategies or prospects. In addition, from time to time, XTL or its representatives
have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use
of forward-looking words such as &quot;believe,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;may,&quot;
&quot;should&quot; or &quot;anticipate&quot; or their negatives or other variations of these words or other comparable words or
by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may
be included in, but are not limited to, various filings made by XTL with the U.S. Securities and Exchange Commission, press releases
or oral statements made by or with the approval of one of XTL&rsquo;s authorized executive officers. Forward-looking statements
relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements
relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause
XTL&rsquo;s actual results to differ materially from any future results expressed or implied by the forward-looking statements.
Many factors could cause XTL&rsquo;s actual activities or results to differ materially from the activities and results anticipated
in such forward-looking statements, including, but not limited to, the factors summarized in XTL&rsquo;s filings with the SEC and
in its periodic filings with the TASE. In addition, XTL operates in an industry sector where securities values are highly volatile
and may be influenced by economic and other factors beyond its control. XTL does not undertake any obligation to publicly update
these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors
associated with an investment in our ADSs or ordinary shares which are included in our Form 20-F filed with the U.S. Securities
and Exchange Commission on March 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>For further information, please contact:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Relations, XTL Biopharmaceuticals
Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: +972 9 955 7080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: <FONT STYLE="color: blue"><U>ir@xtlbio.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: blue"><U>www.xtlbio.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stephanie Carrington</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ICR, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">646-277-1282</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: blue"><U>Stephanie.Carrington@icrinc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Media</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">James Heins</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ICR, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">203-682-8251</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: blue"><U>James.Heins@icrinc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 25%; padding: 0; text-align: center">&nbsp;</TD><TD STYLE="width: 50%; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XTL Biopharmaceuticals Ltd.</FONT></TD><TD STYLE="width: 25%; padding: 0; text-align: center">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding: 0; text-align: center">&nbsp;</TD><TD STYLE="padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5 Hacharoshet Street, Raanana, 43656, Israel</FONT></TD><TD STYLE="padding: 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding: 0; text-align: center">&nbsp;</TD><TD STYLE="padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tel: +972 9 955 7080; email: <U>ir@xtlbio.com</U></FONT></TD><TD STYLE="padding: 0; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- /\# 2(  A$! Q$!_\0
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M:0K9NZ*6_>,G7VJ3P==7L^FL+QG?#_(S]<5)XKOCI]@)D178L!AJE\+W9O\
M31.R*K9QA:MN7U7X5:^_4S2C];^)WMMT-VBL[5M:L]'AWW#_ #'[J+U-<9=^
M.]0DD/V2*.)>P8;C44<)5K*\5H:5\91HNTGKV/1**\SB\;:Q&P\PQ.N>04P:
MZK1/%MKJCB"9?(N#T4GAOH:NK@*U)<S5UY$4<?0JRY4[/S.BHHHKC.T****
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MHYKQZ&E6/JCU*W\.7H?.P^Z*]D\-?$O0-)\/V=E<?:/.AC"MM3(S7E(T;4P
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M288SG J^D:QC"C%.HH @N+99QS2P6ZP+A:FHH 9)$L@PPS5"72(9"3@5I44
792:+$IR0*O0VL<(^4"IZ* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
